AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15259283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 9987624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 64
Study 9987624 — intervention group
Group type: COMPARATOR
Intervention: 0.25% timolol
Number of subjects: 64
Study 7487618 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (0.2%) given topically twice daily for 1 week
Number of subjects: 21
Study 7487618 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated contralateral control eyes
Number of subjects: 21
Study 2248390 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine epidural anesthesia without fentanyl (group 1)
Number of subjects: 2
Study 2248390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural anesthesia with 100 micrograms of fentanyl (group 2)
Number of subjects: 2
Study 6990669 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wound drape (Vi-drape)
Number of subjects: 289
Study 6990669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drape)
Number of subjects: 289
Study 30665882 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) including decision aids
Number of subjects: 115
Study 30665882 — intervention group
Group type: COMPARATOR
Intervention: Control group (consultation with the hospital social service)
Number of subjects: 115
Study 28422874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at 0.2 μg/kg/h
Number of subjects: 93
Study 28422874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at 0.4 μg/kg/h
Number of subjects: 93
Study 28422874 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 93
Study 26074397 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 2887
Study 26074397 — intervention group
Group type: COMPARATOR
Intervention: Sequential docetaxel
Number of subjects: 2887
Study 26074397 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in ER-positive tumours with Ki67≥14%
Number of subjects: 2887
Study 26074397 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in ER-positive patients with high Ki67
Number of subjects: 2887
Study 26074397 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes in highly proliferative ER-positive disease
Number of subjects: 2887
Study 25039244 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% potassium hydroxide (KOH) solution
Number of subjects: 60
Study 25039244 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.5% 5‐fluorouracil (5‐FU) and 10% salicylic acid (SA) combination
Number of subjects: 60
Study 22647439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 1.5 mcg/kg
Number of subjects: 30
Study 22647439 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 30
Study 19605829 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of APOE genotyping results
Number of subjects: 162
Study 19605829 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure of APOE genotyping results
Number of subjects: 162
Study 19605829 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure subgroup carrying the APOE epsilon4 allele
Number of subjects: 162
Study 19605829 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon4-negative subgroup
Number of subjects: 162
Study 19605829 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline scores for anxiety and depression
Number of subjects: 162
Study 17445898 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sub‐Tenon's capsule injection of 3 ml of 0.75% ropivacaine
Number of subjects: 98
Study 17445898 — intervention group
Group type: COMPARATOR
Intervention: Control group (sub‐Tenon's capsule injection of 3 ml of saline)
Number of subjects: 98
Study 16113430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (inhaled corticosteroid)
Number of subjects: 0
Study 12575211 — intervention group
Group type: EXPERIMENTAL
Intervention: First aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC)
Number of subjects: 32
Study 12575211 — intervention group
Group type: EXPERIMENTAL
Intervention: Second aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and 1 x 10(6) units of aprotinin for intravenous bolus)
Number of subjects: 32
Study 12575211 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone combined with aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and amrinone bolus of 1 mg/kg followed by maintenance of 8 micrograms/kg.min)
Number of subjects: 32
Study 12575211 — intervention group
Group type: COMPARATOR
Intervention: Control group (equivalence without aprotinin)
Number of subjects: 32
Study 9613383 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution therapy (IHT) for 6 weeks with venesection and volume replacement using hydroxyethylstarch, targeting a haematocrit of 35%.
Number of subjects: 2
Study 9613383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 2
Study 7852229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intramuscular hepatitis B vaccine (2 micrograms at first, followed by 1 microgram each at 1, 2, and 6 months)
Number of subjects: 120
Study 7852229 — intervention group
Group type: COMPARATOR
Intervention: Standard dose intramuscular hepatitis B vaccine (10 micrograms each at 0, 1, and 6 months)
Number of subjects: 120
Study 30902602 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during extraction
Number of subjects: 40
Study 30902602 — intervention group
Group type: COMPARATOR
Intervention: Extraction without music (control group)
Number of subjects: 40
Study 28244261 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289
Study 28244261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study 25713462 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated neurocognitive therapy (INT)
Number of subjects: 156
Study 25713462 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 156
Study 22923232 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-1 (1 min rest between intervals)
Number of subjects: 12
Study 22923232 — intervention group
Group type: COMPARATOR
Intervention: HIT-3 (3 min rest between intervals)
Number of subjects: 12
Study 20683104 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg b.d.)
Number of subjects: 50
Study 20683104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17224034 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered in the wound
Number of subjects: 10
Study 17224034 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in the wound
Number of subjects: 10
Study 16167244 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (35-45 Gy within 4-5 weeks) plus preoperative chemotherapy with 5-fluorouracil followed by lower-anterior resection (Group A)
Number of subjects: 157
Study 16167244 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by lower-anterior resection (Group B)
Number of subjects: 157
Study 16167244 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection only (Group C)
Number of subjects: 157
Study 16167244 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B and C)
Number of subjects: 157
Study 12072716 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK procedure using Keratom II Coherent‐Schwind excimer laser and Moria Model One microkeratome (150-microm head)
Number of subjects: 57
Study 12072716 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK procedure
Number of subjects: 57
Study 10535234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based contingency management (CM) treatment
Number of subjects: 81
Study 10535234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive self-control (SC) treatment
Number of subjects: 81
Study 10535234 — intervention group
Group type: COMPARATOR
Intervention: Education support (ES) control condition
Number of subjects: 81
Study 8849353 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management group
Number of subjects: 141
Study 8849353 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 141
Study 8849353 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 141
Study 2088462 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP) at 200% of recommended dietary allowances (RDA)
Number of subjects: 17
Study 2088462 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LP) at 100% of recommended dietary allowances (RDA)
Number of subjects: 17
Study 7024200 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group with enhanced commitment (contracts signed by participant and at least one friend, relative, or peer)
Number of subjects: 106
Study 7024200 — intervention group
Group type: COMPARATOR
Intervention: Control group with baseline commitment (contracts signed by participant only)
Number of subjects: 106
Study 31569161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) via a mobile device
Number of subjects: 45
Study 31569161 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 45
Study 31511230 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori treatment with amoxicillin and omeprazole for two weeks
Number of subjects: 3365
Study 31511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (C, E, and selenium) for 7.3 years
Number of subjects: 3365
Study 31511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation (extract and oil) for 7.3 years
Number of subjects: 3365
Study 28641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular immunotherapy combined with bortezomib (combined therapy group)
Number of subjects: 76
Study 28641642 — intervention group
Group type: COMPARATOR
Intervention: Only chemotherapy including bortezomib (single chemotherapy as control group)
Number of subjects: 76
Study 25528325 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for Tdap vaccine
Number of subjects: 0
Study 25528325 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for MCV4 vaccine
Number of subjects: 0
Study 25528325 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for HPV vaccine
Number of subjects: 0
Study 25528325 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for influenza vaccine
Number of subjects: 0
Study 24242195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth follow-up
Number of subjects: 0
Study 24242195 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (home-based program supported by telephone calls)
Number of subjects: 186
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise intervention (three weekly supervised sessions in a fitness center)
Number of subjects: 186
Study 21883103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 186
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise intervention
Number of subjects: 186
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 186
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (lifestyle and structured)
Number of subjects: 186
Study 21883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 186
Study 19596729 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted discomfort-reducing intervention (verbal suggestions, visual focusing activity, ethyl chloride)
Number of subjects: 41
Study 19596729 — intervention group
Group type: COMPARATOR
Intervention: Office routine control group
Number of subjects: 41
Study 18265707 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium oxalate gel applied prior to bonding procedures
Number of subjects: 0
Study 18265707 — intervention group
Group type: COMPARATOR
Intervention: Single Bond (3M ESPE), One‐Up Bond F (Tokuyama), and AdheSE (Ivoclar Vivadent)
Number of subjects: 0
Study 15221991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg) plus 5-fluorouracil/leucovorin (5-FU/LV)
Number of subjects: 104
Study 15221991 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5-FU/LV) alone
Number of subjects: 104
Study 12149107 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of tap water
Number of subjects: 14
Study 12149107 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of tap water (control)
Number of subjects: 14
Study 12149107 — intervention group
Group type: EXPERIMENTAL
Intervention: Water ingestion in transplant recipients
Number of subjects: 14
Study 10356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate 50 mg/kg
Number of subjects: 15
Study 10356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine 2 mg/kg
Number of subjects: 15
Study 10356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine 3 mg/kg
Number of subjects: 15
Study 8134070 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochures
Number of subjects: 108
Study 8134070 — intervention group
Group type: COMPARATOR
Intervention: No educational brochures (Control)
Number of subjects: 108
Study 2674067 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 2674067 — intervention group
Group type: COMPARATOR
Intervention: Perioperative transfusion
Number of subjects: 0
Study 1102383 — intervention group
Group type: EXPERIMENTAL
Intervention: Loesferron effervescent iron tablet
Number of subjects: 57
Study 30799502 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib + venetoclax + obinutuzumab (IVO) with IM
Number of subjects: 0
Study 30799502 — intervention group
Group type: EXPERIMENTAL
Intervention: IVO + IM for patients without minimal residual disease complete response (MRD‐CR)
Number of subjects: 0
Study 30799502 — intervention group
Group type: EXPERIMENTAL
Intervention: IVO + IM discontinuation for patients with MRD‐CR
Number of subjects: 0
Study 29233141 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based neck-specific exercise programme
Number of subjects: 140
Study 29233141 — intervention group
Group type: COMPARATOR
Intervention: Neck-specific exercises at a physiotherapy clinic
Number of subjects: 140
Study 26231855 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting intervention (n=644 mothers)
Number of subjects: 1238
Study 26231855 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=594 mothers)
Number of subjects: 1238
Study 27129119 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Number of subjects: 27
Study 27129119 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg
Number of subjects: 27
Study 27129119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22944150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interactive and personally weight-relevant text-messages
Number of subjects: 170
Study 22944150 — intervention group
Group type: COMPARATOR
Intervention: Monthly e-newsletters
Number of subjects: 170
Study 18937318 — intervention group
Group type: COMPARATOR
Intervention: ABMT (Autologous Bone Marrow Transplantation), n = 20
Number of subjects: 72
Study 18937318 — intervention group
Group type: COMPARATOR
Intervention: 13-cis-retinoic acid (13-cis-RA), n = 23
Number of subjects: 72
Study 18937318 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT and 13-cis-RA, n = 6
Number of subjects: 72
Study 17456380 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for two months
Number of subjects: 19
Study 15824079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antero-apical (AA) pad position
Number of subjects: 307
Study 15824079 — intervention group
Group type: COMPARATOR
Intervention: Antero-posterior (AP) pad position
Number of subjects: 307
Study 12205284 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (oral solution) at a mean dose of 1.38 mg/d (range: 0.02‐0.06 mg/kg/d) for 48 weeks
Number of subjects: 77
Study 12205284 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (previously treated group)
Number of subjects: 77
Study 12205284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previously treated group)
Number of subjects: 77
Study 12205284 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 77
Study 9858353 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 1-hour small group counseling sessions with a booster session at 2 months
Number of subjects: 996
Study 9858353 — intervention group
Group type: COMPARATOR
Intervention: Two 20-minute individual counseling sessions
Number of subjects: 996
Study 7618457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone agonist treatment (D‐Trp‐6‐LHRH depot) before hysterectomy
Number of subjects: 50
Study 7618457 — intervention group
Group type: COMPARATOR
Intervention: Immediate hysterectomy
Number of subjects: 50
Study 2392858 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 100 mg Trapidil (Rocornal) daily
Number of subjects: 41
Study 2392858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2392858 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil
Number of subjects: 41
Study 344090 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine 200 mg three times daily
Number of subjects: 0
Study 344090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29381690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day until progression or unacceptable toxicity
Number of subjects: 95
Study 29381690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 29381690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 95
Study 26899745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone 500 mg every 12 hours for 3 days
Number of subjects: 71
Study 26899745 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 500 mg every 12 hours for 7 days
Number of subjects: 71
Study 24429901 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin for 12 weeks
Number of subjects: 22
Study 24429901 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin for 12 weeks
Number of subjects: 22
Study 22633302 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartNet Ventricular Support System
Number of subjects: 210
Study 22633302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 20552087 — intervention group
Group type: EXPERIMENTAL
Intervention: All-composite resin crowns
Number of subjects: 200
Study 20552087 — intervention group
Group type: COMPARATOR
Intervention: All-ceramic crowns
Number of subjects: 200
Study 18606019 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture at LI-2
Number of subjects: 20
Study 18606019 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 20
Study 16238908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 40,000 U once weekly
Number of subjects: 533
Study 16238908 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (DARB) 2.25 mcg/kg once weekly
Number of subjects: 533
Study 12090862 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380)
Number of subjects: 2763
Study 12090862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763
Study 10334165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation group (lidocaine spray, atropine i.m. and diazepam i.v.)
Number of subjects: 100
Study 10334165 — intervention group
Group type: COMPARATOR
Intervention: Nonsedation group (lidocaine spray and atropine sulfate i.m.)
Number of subjects: 100
Study 10334165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 8943447 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplane transesophageal echocardiography
Number of subjects: 50
Study 8943447 — intervention group
Group type: COMPARATOR
Intervention: Biplane transesophageal echocardiography
Number of subjects: 50
Study 1769643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxilofrine
Number of subjects: 60
Study 1769643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6801516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Nitrogen Vivonex
Number of subjects: 4
Study 6801516 — intervention group
Group type: EXPERIMENTAL
Intervention: Product MJ7041
Number of subjects: 4
Study 6801516 — intervention group
Group type: COMPARATOR
Intervention: Solid food
Number of subjects: 4
Study 31628482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 64
Study 31628482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31628482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (in subjects not using biologic therapy)
Number of subjects: 64
Study 31628482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subjects not using biologic therapy)
Number of subjects: 64
Study 31401683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) plus intravitreal erythropoietin (EPO)
Number of subjects: 34
Study 31401683 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone
Number of subjects: 34
Study 27996199 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intermittent TAP catheters with bupivacaine
Number of subjects: 93
Study 27996199 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intermittent TAP catheters with saline
Number of subjects: 93
Study 26307030 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1256
Study 26307030 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and former smokers
Number of subjects: 1256